Magnetic resonance metabolic imaging of glioma

Science Translational Medicine

Volumn 4, Issue 116, 2012, Pages

  Metellus, Philippe ^a,b   Figarella Branger, Dominique ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; 4 AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; CANCER GRADING; CANCER PATIENT; CARCINOGENESIS; ENZYME ACTIVITY; ENZYME ANALYSIS; EPIGENETICS; GENE; GENE MUTATION; GENOMICS; GLIOBLASTOMA; GLIOMA; GLYCOLYSIS; HETEROZYGOTE; HUMAN; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; LIQUID CHROMATOGRAPHY; MAGNETIC RESONANCE METABOLIC IMAGING; MASS SPECTROMETRY; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT MONITORING; PILOCYTIC ASTROCYTOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ARTICLE; BRAIN TUMOR; ENZYMOLOGY; GENETICS; METABOLISM; METHODOLOGY; MUTATION;

BRAIN NEOPLASMS; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MAGNETIC RESONANCE IMAGING; MUTATION; PROGNOSIS;

EID: 84855707107     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003591     Document Type: Review

References (26)

1. O. C. Andronesi, G. S. Kim, E. Gerstner, T. Batchelor, A. A. Tzika, V. R. Fantin, M. G. Vander Heiden, A. G. Sorensen, Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci. Transl. Med., 4, 116ra4 (2012).
2. A. Elkhaled, L. E. Jalbert, J. J. Phillips, H. A. I. Yoshihara, R. Parvataneni, R. Srinivasan, G. Bourne, M. S. Berger, S. M. Chang, S. Cha, S. J. Nelson, Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci. Transl. Med., 4,116ra5 (2012).
3. D. W. Parsons, S. Jones, X. Zhang, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I.-M. Siu, G. L. Gallia, A. Olivi, R. McLendon, B. A. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D. A. Busam, H. Tekleab, L. A. Diaz Jr., J. Hartigan, D. R. Smith, R. L. Strausberg, S. K. N. Marie, S. M. O. Shinjo, H. Yan, G. J. Riggins, D. D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. E. Velculescu, K. W. Kinzler, An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
4. H. Yan, D. W. Parsons, G. Jin, R. McLendon, B. A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G. J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K. W. Kinzler, V. E. Velculescu, B. Vogelstein, D. D. Bigner, IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
5. M. Sanson, Y. Marie, S. Paris, A. Idbaih, J. Laffaire, F. Ducray, S. El Hallani, B. Boisselier, K. Mokhtari, K. Hoang-Xuan, J. Y. Delattre, Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 27, 4150-4154 (2009).
6. T. Watanabe, S. Nobusawa, P. Kleihues, H. Ohgaki, IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 174, 1149-1153 (2009).
7. M. J. van den Bent, H. J. Dubbink, Y. Marie, A. A. Brandes, M. J. Taphoorn, P. Wesseling, M. Frenay, C. C. Tijssen, D. Lacombe, A. Idbaih, R. van Marion, J. M. Kros, W. N. Dinjens, T. Gorlia, M. Sanson, IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 16, 1597-1604 (2010).
8. Y. H. Kim, S. Nobusawa, M. Mittelbronn, W. Paulus, B. Brokinkel, K. Keyvani, U. Sure, K. Wrede, Y. Nakazato, Y. Tanaka, A. Vital, L. Mariani, R. Stawski, T. Watanabe, U. De Girolami, P. Kleihues, H. Ohgaki, Molecular classification of low-grade diffuse gliomas. Am. J. Pathol. 177, 2708-2714 (2010).
9. S. Zhao, Y. Lin, W. Xu, W. Jiang, Z. Zha, P. Wang, W. Yu, Z. Li, L. Gong, Y. Peng, J. Ding, Q. Lei, K.-L. Guan, Y. Xiong, Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324, 261-265 (2009).
10. L. Dang, D. W. White, S. Gross, B. D. Bennett, M. A. Bittinger, E. M. Driggers, V. R. Fantin, H. G. Jang, S. Jin, M. C. Keenan, K. M. Marks, R. M. Prins, P. S. Ward, K. E. Yen, L. M. Liau, J. D. Rabinowitz, L. C. Cantley, C. B. Thompson, M. G. Vander Heiden, S. M. Su, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009).
11. P. S. Ward, J. Patel, D. R. Wise, O. Abdel-Wahab, B. D. Bennett, H. A. Coller, J. R. Cross, V. R. Fantin, C. V. Hedvat, A. E. Perl, J. D. Rabinowitz, M. Carroll, S. M. Su, K. A. Sharp, R. L. Levine, C. B. Thompson, The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225-234 (2010).
12. O. De Witte, F. Lefranc, M. Levivier, I. Salmon, J. Brotchi, S. Goldman, FDG-PET as a prognostic factor in high-grade astrocytoma. J. Neurooncol. 49, 157-163 (2000).
13. P. Metellus, C. Colin, D. Taieb, E. Guedj, I. Nanni-Metellus, A. M. de Paula, C. Colavolpe, S. Fuentes, H. Dufour, M. Barrie, O. Chinot, L. Ouafik, D. Figarella-Branger, IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J. Neurooncol. 105, 591-600 (2011).
14. S. C. Williams, M. A. Karajannis, L. Chiriboga, J. G. Golfinos, A. von Deimling, D. Zagzag, R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathol. 121, 279-281 (2011).
15. S. Gross, R. A. Cairns, M. D. Minden, E. M. Driggers, M. A. Bittinger, H. G. Jang, M. Sasaki, S. Jin, D. P. Schenkein, S. M. Su, L. Dang, V. R. Fantin, T. W. Mak, Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339-344 (2010).
16. C. Hartmann, J. Meyer, J. Balss, D. Capper, W. Mueller, A. Christians, J. Felsberg, M. Wolter, C. Mawrin, W. Wick, M. Weller, C. Herold-Mende, A. Unterberg, J. W. Jeuken, P. Wesseling, G. Reifenberger, A. von Deimling, Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol. 118, 469-474 (2009).
17. D. Capper, M. Simon, C.-D. Langhans, J. G. Okun, J. C. Tonn, M. Weller, A. V. Deimling, C. Hartmann for the German Glioma Network, 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int. J. Cancer A. (2011).
18. P. Metellus, B. Coulibaly, C. Colin, A. M. de Paula, A. Vasiljevic, D. Taieb, A. Barlier, B. Boisselier, K. Mokhtari, X. W. Wang, A. Loundou, F. Chapon, S. Pineau, L. Ouafik, O. Chinot, D. Figarella-Branger, Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 120, 719-729 (2010).
19. M. Preusser, D. Capper, C. Hartmann; Euro-CNS Research Committee, IDH testing in diagnostic neuropathology: Review and practical guideline article invited by the Euro-CNS research committee. Clin. Neuropathol. 30, 217-230 (2011).
20. D. Capper, H. Zentgraf, J. Balss, C. Hartmann, A. von Deimling, Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 118, 599-601 (2009).
21. F. Sahm, D. Capper, S. Pusch, J. Balss, A. Koch, C. D. Langhans, J. G. Okun, A. von Deimling, Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. Brain Pathol. 22, 26-31 (2012).
22. N. K. Kloosterhof, L. B. Bralten, H. J. Dubbink, P. J. French, M. J. van den Bent, Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma? Lancet Oncol. 12, 83-91 (2011).
23. H. J. Dubbink, W. Taal, R. van Marion, J. M. Kros, I. van Heuvel, J. E. Bromberg, B. A. Zonnenberg, C. B. Zonnenberg, T. J. Postma, J. M. Gijtenbeek, W. Boogerd, F. H. Groenendijk, P. A. Smitt, W. N. Dinjens, M. J. van den Bent, IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73, 1792-1795 (2009).
24. W. Xu, H. Yang, Y. Liu, Y. Yang, P. Wang, S. H. Kim, S. Ito, C. Yang, P. Wang, M. T. Xiao, L. X. Liu, W. Q. Jiang, J. Liu, J. Y. Zhang, B. Wang, S. Frye, Y. Zhang, Y. H. Xu, Q. Y. Lei, K. L. Guan, S. M. Zhao, Y. Xiong, Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate- dependent dioxygenases. Cancer Cell 19, 17-30 (2011).
25. M. E. Figueroa, O. Abdel-Wahab, C. Lu, P. S. Ward, J. Patel, A. Shih, Y. Li, N. Bhagwat, A. Vasanthakumar, H. F. Fernandez, M. S. Tallman, Z. Sun, K. Wolniak, J. K. Peeters, W. Liu, S. E. Choe, V. R. Fantin, E. Paietta, B. Löwenberg, J. D. Licht, L. A. Godley, R. Delwel, P. J. Valk, C. B. Thompson, R. L. Levine, A. Melnick, Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567 (2010).
26. B. Malzkorn, M. Wolter, M. J. Riemenschneider, G. Reifenberger, Unraveling the glioma epigenome: From molecular mechanisms to novel biomarkers and therapeutic targets. Brain Pathol. 21, 619-632 (2011).